Epigenomics AG
· ISIN: DE000A32VN83
· EQS - adhoc news
Executive Board member Jens Ravens leaves the Company on April 30, 2024
Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor
Smart tools for smart investors can be found in our Tools section
Corporate News Epigenomics AG
In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
This might be interesting for you as well
30 October 2023 03:49PM
Executive Board member Jens Ravens leaves the Company on April 30, 2024
Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024
Berlin, Germany, October 30, 2023 – Jens Ravens, Executive Board member of Epigenomics AG (Frankfurt General Standard: ECX1, the “Company”), leaves the Executive Board of the Company with effect as of April 30, 2024, due to the successful transfer of nearly all...
Epigenomics AG
10 October 2023 09:10PM
Epigenomics AG Announces Closing of Agreement on the Acquisition of Almost All of the Company's Assets and Adjustment of Guidance for 2023
Epigenomics AG Announces Closing of Agreement on the Acquisition of Almost All of the Company's Assets and Adjustment of Guidance for 2023
Successful closing of agreement with New Day Diagnostics LLC: transfer of almost all assets
Initial cash payment of USD 0.5 million and interest in New Day Diagnostics LLC received; eligible for additional pa...
Epigenomics AG
10 October 2023 08:56PM
Closing of Agreement on the Acquisition of Almost All Assets and Adjustment of Guidance for 2023
Closing of Agreement on the Acquisition of Almost All Assets and Adjustment of Guidance for 2023
Berlin, Germany, October 10, 2023 – Epigenomics AG (Frankfurt General Standard: ECX1; the “Company”) closed today the agreement entered into on July 24, 2023 with New Day Diagnostics LLC (“New Day Diagnostics”), a U.S.-based diagnostics and contract re...
Epigenomics AG
11 September 2023 03:54PM
Approval by the Extraordinary General Meeting of the acquisition of almost all assets and corresponding change of the statutory purpose of the Company
Approval by the Extraordinary General Meeting of the acquisition of almost all assets and corresponding change of the statutory purpose of the Company
Berlin, Germany, September 11, 2023 – The Extraordinary General Meeting of Epigenomics AG (Frankfurt General Standard: ECX1; the “Company”) among other items approved today the agreement (the “Agree...
Epigenomics AG
05 September 2023 05:20PM
Pareto and Warburg publish analyst research reports
Epigenomics AG: Pareto and Warburg publish analyst research reports
Analysts consider acceptance of New Day Diagnostics' purchase offer advantageous for shareholders
Buy recommendation with price targets of EUR 3.15 and EUR 3.30
Berlin (Germany), September 5, 2023 - Epigenomics AG (Frankfurt General Standard: ECX1; the "Company") announces that...
Epigenomics AG
10 August 2023 08:00AM
Epigenomics AG publishes financial results for the first six months 2023
Epigenomics AG publishes financial results for the first six months 2023
Berlin (Germany), August 10, 2023 - Epigenomics AG (FSE: ECX, the "Company") today reported financial results (IFRS, unaudited) for the second quarter and first half of 2023.
Operational developments
As the Company was not able to raise additional capital to secure funding...
Epigenomics AG
02 August 2023 10:36AM
1
Epigenomics AG: Capital reduction planned at a ratio of 5 : 1
Berlin, August 2, 2023 – The Executive Board and the Supervisory Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") have decided to propose to the extraordinary Shareholders' Meeting, which is to be convened on September 11, 2023, to resolve, in additi...
Epigenomics AG
02 August 2023 10:36AM
Epigenomics AG: Capital reduction planned at a ratio of 5: 1
Epigenomics AG: Capital reduction planned at a ratio of 5 : 1
Berlin, August 2, 2023 – The Executive Board and the Supervisory Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") have decided to propose to the extraordinary Shareholders' Meeting, which is to be convened on September 11, 2023, to resolve, in additi...
Epigenomics AG
24 July 2023 06:40PM
Epigenomics AG Announces Successful Agreement on the Acquisition of Significant Assets
Epigenomics AG Announces Successful Agreement on the Acquisition of Significant Assets
Acquirer is U.S. full-service diagnostics and CRO services company New Day Diagnostics LLC
Purchase price of up to USD 12.05 million plus license and earn-out payments
Berlin (Germany), July 24, 2023 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EP...
Epigenomics AG
24 July 2023 06:40PM
Epigenomics AG Announces Successful Agreement on the Acquisition of Significant Assets
Epigenomics AG Announces Successful Agreement on the Acquisition of Significant Assets
Acquirer is U.S. full-service diagnostics and CRO services company New Day Diagnostics LLC
Purchase price of up to USD 12.05 million plus license and earn-out payments
Berlin (Germany), July 24, 2023 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EP...
Epigenomics AG
24 July 2023 06:29PM
Agreement on the Acquisition of Almost All Assets
Epigenomics AG: Agreement on the Acquisition of Almost All Assets
Berlin, Germany, July 24, 2023 – Epigenomics AG (Frankfurt Prime Standard: ECX1, OTCQX: EPGNY; the “Company”) entered today into an agreement (the “Agreement”) on the acquisition of almost all its assets with New Day Diagnostics LLC (the “Acquirer”), a U.S. full-service diagnostics ...
Epigenomics AG
24 July 2023 06:29PM
Epigenomics AG: Agreement on the Acquisition of Almost All Assets
Epigenomics AG: Agreement on the Acquisition of Almost All Assets
Berlin, Germany, July 24, 2023 – Epigenomics AG (Frankfurt Prime Standard: ECX1, OTCQX: EPGNY; the “Company”) entered today into an agreement (the “Agreement”) on the acquisition of almost all its assets with New Day Diagnostics LLC (the “Acquirer”), a U.S. full-service diagnostics ...
Epigenomics AG
12 June 2023 10:21AM
Negotiations on the Acquisitions of Almost All Assets
Negotiations on the Acquisitions of Almost All Assets
Berlin, Germany, June 12, 2023 – Epigenomics AG (Frankfurt Prime Standard: ECX1, OTCQX: EPGNY; the “Company”) is in well advanced negotiations with an US based strategic investor (“Acquiror”) on the acquisition of almost all assets of the Company. Binding agreements have not yet been concluded,...
Epigenomics AG
12 June 2023 10:21AM
Epigenomics AG: Negotiations on the Acquisitions of Almost All Assets
Negotiations on the Acquisitions of Almost All Assets
Berlin, Germany, June 12, 2023 – Epigenomics AG (Frankfurt Prime Standard: ECX1, OTCQX: EPGNY; the “Company”) is in well advanced negotiations with an US based strategic investor (“Acquiror”) on the acquisition of almost all assets of the Company. Binding agreements have not yet been concluded,...
Epigenomics AG
31 May 2023 08:00AM
Epigenomics AG Reports Financial Results for the First Quarter of 2023
Epigenomics AG Reports Financial Results for the First Quarter of 2023
Berlin (Germany) and San Diego, CA (USA), May 31, 2023 - Epigenomics AG (FSE: ECX, the "Company") today reported financial results (IFRS, unaudited) for the first three months of 2023.
Financial key figures
Revenues in the first quarter of 2023 increased slightly year-on-yea...
Epigenomics AG
31 May 2023 08:00AM
Epigenomics AG Reports Financial Results for the First Quarter of 2023
Epigenomics AG Reports Financial Results for the First Quarter of 2023
Berlin (Germany) and San Diego, CA (USA), May 31, 2023 - Epigenomics AG (FSE: ECX, the "Company") today reported financial results (IFRS, unaudited) for the first three months of 2023.
Financial key figures
Revenues in the first quarter of 2023 increased slightly year-on-yea...
Epigenomics AG
19 May 2023 06:00PM
Member of the Executive Board and Chief Scientific Officer Andrew Lukowiak Resigns
Epigenomics AG: Member of the Executive Board and Chief Scientific Officer Andrew Lukowiak Resigns
Berlin (Germany), May 19, 2023 -The Member of the Executive Board, President, and Chief Scientific Officer of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company"), Dr. Andrew Lukowiak, and the Company's Supervisory Board toda...
Epigenomics AG
19 May 2023 06:00PM
Epigenomics AG: Member of the Executive Board and Chief Scientific Officer Andrew Lukowiak Resigns
Epigenomics AG: Member of the Executive Board and Chief Scientific Officer Andrew Lukowiak Resigns
Berlin (Germany), May 19, 2023 -The Member of the Executive Board, President, and Chief Scientific Officer of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company"), Dr. Andrew Lukowiak, and the Company's Supervisory Board toda...
Epigenomics AG
19 May 2023 05:48PM
Changes in the Management
Epigenomics AG: Changes in the Management
Berlin, Germany, May 19, 2023 – In connection with its revised strategy, Epigenomics AG (Frankfurt Prime Standard: ECX1, OTCQX: EPGNY) announces changes to its Executive Board. The Member of the Executive Board, President, and Chief Scientific Officer of Epigenomics AG (Frankfurt Prime Standard: ECX1, OTCQ...
Epigenomics AG
19 May 2023 05:48PM
Epigenomics AG: Changes in the Management
Epigenomics AG: Changes in the Management
Berlin, Germany, May 19, 2023 – In connection with its revised strategy, Epigenomics AG (Frankfurt Prime Standard: ECX1, OTCQX: EPGNY) announces changes to its Executive Board. The Member of the Executive Board, President, and Chief Scientific Officer of Epigenomics AG (Frankfurt Prime Standard: ECX1, OTCQ...
Epigenomics AG
28 April 2023 08:00AM
Epigenomics AG publishes financial results for fiscal year 2022
Epigenomics AG publishes financial results for fiscal year 2022
Berlin (Germany) and San Diego, CA (U.S.A.), April 28, 2023 - Epigenomics AG (FSE: ECX, the "Company") today reported financial results (according to IFRS) for fiscal year 2022.
FINANCIAL RESULTS 2022
Revenues decreased to EUR 0.5 million in fiscal year 2022, compared to EUR 6.2 mi...
Epigenomics AG
28 April 2023 08:00AM
Epigenomics AG publishes financial results for fiscal year 2022
Epigenomics AG publishes financial results for fiscal year 2022
Berlin (Germany) and San Diego, CA (U.S.A.), April 28, 2023 - Epigenomics AG (FSE: ECX, the "Company") today reported financial results (according to IFRS) for fiscal year 2022.
FINANCIAL RESULTS 2022
Revenues decreased to EUR 0.5 million in fiscal year 2022, compared to EUR 6.2 mi...
Epigenomics AG
12 April 2023 08:05PM
Chief Executive Officer Greg Hamilton Resigns
Epigenomics AG: Chief Executive Officer Greg Hamilton Resigns
Berlin (Germany), April 12, 2023 - The Chief Executive Officer of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company"), Greg Hamilton, and the Company's Supervisory Board agreed on his resignation from the Company and the Executive Board effective June 30, 2023. ...
Epigenomics AG
12 April 2023 08:05PM
Epigenomics AG: Chief Executive Officer Greg Hamilton Resigns
Epigenomics AG: Chief Executive Officer Greg Hamilton Resigns
Berlin (Germany), April 12, 2023 - The Chief Executive Officer of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company"), Greg Hamilton, and the Company's Supervisory Board agreed on his resignation from the Company and the Executive Board effective June 30, 2023. ...
Epigenomics AG
12 April 2023 07:56PM
Changes in the Management
Epigenomics AG: Changes in the Management
Berlin, Germany, April 12, 2023 – In connection with its revised strategy, Epigenomics AG (Frankfurt Prime Standard: ECX1, OTCQX: EPGNY) announces changes to its Executive Board. The Chief Executive Officer of Epigenomics AG (Frankfurt Prime Standard: ECX1, OTCQX: EPGNY; the "Company"), Mr. Greg Hamilton, ...
Epigenomics AG
12 April 2023 07:56PM
Epigenomics AG: Changes in the Management
Epigenomics AG: Changes in the Management
Berlin, Germany, April 12, 2023 – In connection with its revised strategy, Epigenomics AG (Frankfurt Prime Standard: ECX1, OTCQX: EPGNY) announces changes to its Executive Board. The Chief Executive Officer of Epigenomics AG (Frankfurt Prime Standard: ECX1, OTCQX: EPGNY; the "Company"), Mr. Greg Hamilton, ...
Epigenomics AG
20 March 2023 08:19PM
Adjustment of guidance and notice of loss pursuant to sec. 92 para. 1 of the German Stock Corporation Act
Adjustment of guidance and notice of loss pursuant to sec. 92 para. 1 of the German Stock Corporation Act
Berlin, Germany, March 20, 2023 – The Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX1, OTCQX: EPGNY; the “Company”) now expects for the entire financial year 2022 an adjusted EBITDA (before share-based payment expenses) in th...
Epigenomics AG
20 March 2023 08:19PM
Epigenomics AG: Adjustment of guidance and notice of loss pursuant to sec. 92 para. 1 of the German Stock Corporation Act
Adjustment of guidance and notice of loss pursuant to sec. 92 para. 1 of the German Stock Corporation Act
Berlin, Germany, March 20, 2023 – The Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX1, OTCQX: EPGNY; the “Company”) now expects for the entire financial year 2022 an adjusted EBITDA (before share-based payment expenses) in th...
Epigenomics AG
10 March 2023 09:37AM
Revocation of admission to the Prime Standard (sub-segment of the regulated market with additional post-admission obligations)
Epigenomics AG: Revocation of admission to the Prime Standard (sub-segment of the regulated market with additional post-admission obligations)
Revocation will become effective at the end of June 9, 2023
Admission to trading in the General Standard expected on June 12, 2023
Termination of the ADR program effective as of April 7, 2023
Berlin (Germ...
Epigenomics AG
10 March 2023 09:37AM
Epigenomics AG: Revocation of admission to the Prime Standard (sub-segment of the regulated market with additional post-admission obligations)
Epigenomics AG: Revocation of admission to the Prime Standard (sub-segment of the regulated market with additional post-admission obligations)
Revocation will become effective at the end of June 9, 2023
Admission to trading in the General Standard expected on June 12, 2023
Termination of the ADR program effective as of April 7, 2023
Berlin (Germ...
Epigenomics AG
15 February 2023 11:18AM
Epigenomics decides to restructure to minimize costs
Epigenomics decides to restructure to minimize costs
Berlin (Germany) and San Diego, CA (U.S.A.) February 15, 2023 – The Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX1, OTCQX: EPGNY; the “Company”) today decided to restructure the Company and significantly reduce the Company's operations. The restructuring is being undertaken wi...
Epigenomics AG
15 February 2023 11:18AM
Epigenomics decides to restructure to minimize costs
Epigenomics decides to restructure to minimize costs
Berlin (Germany) and San Diego, CA (U.S.A.) February 15, 2023 – The Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX1, OTCQX: EPGNY; the “Company”) today decided to restructure the Company and significantly reduce the Company's operations. The restructuring is being undertaken wi...
Epigenomics AG
15 February 2023 11:13AM
Epigenomics resolves on restructuring to minimize costs
Epigenomics resolves on restructuring to minimize costs
Berlin, Germany, February 15, 2023 - Today Epigenomics AG (Frankfurt Prime Standard: ECX1, OTCQX: EPGNY; the “Company”) has decided to restructure the Company and to significantly reduce the Company's operations (the “Restructuring”). The Restructuring is carried out to minimize the Company's...
Epigenomics AG
15 February 2023 11:13AM
Epigenomics resolves on restructuring to minimize costs
Epigenomics resolves on restructuring to minimize costs
Berlin, Germany, February 15, 2023 - Today Epigenomics AG (Frankfurt Prime Standard: ECX1, OTCQX: EPGNY; the “Company”) has decided to restructure the Company and to significantly reduce the Company's operations (the “Restructuring”). The Restructuring is carried out to minimize the Company's...
Epigenomics AG
27 January 2023 06:08PM
Resignation of Supervisory Board Chairman Heino von Prondzynski
Epigenomics AG: Resignation of Supervisory Board Chairman Heino von Prondzynski
Berlin (Germany), January 27, 2023 -The Chairman of the Supervisory Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company"), Heino von Prondzynski, today informed the Boards that he will resign from his mandate effective March 31, 2023, fo...
Epigenomics AG
27 January 2023 02:16PM
Resignation of the Chairman of the Supervisory Board Heino von Prondzynski
Epigenomics AG: Resignation of the Chairman of the Supervisory Board Heino von Prondzynski
Berlin, January 27, 2023 - The Chairman of the Supervisory Board of Epigenomics AG, Heino von Prondzynski, informed the Boards today that he will resign from his mandate effective March 31, 2023, for health reasons and will leave the Supervisory Board at th...
Epigenomics AG
More Epigenomics AG related information
| Type | Total | Last | Made by | Go to |
|---|---|---|---|---|
| Corporate Research | 0 | - | - | Corporate Research |
| Directors Dealings | 1 | 30th December 2022 | Ravens, Jens | DD |
| Short Seller (DE) | 0 | - | - | SSR (DE) |
| Short Seller (UK) | 0 | - | - | SSR (UK) |
Disclaimer:
The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster.
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.
If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.
v.07062023 EN